Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HRS-4642 + SHR-A1904
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**HRS-4642 + SHR-A1904** is an investigational combination therapy consisting of *HRS-4642*, a potent and selective small molecule inhibitor of KRAS G12D, and *SHR-A1904*, an antibody-drug conjugate targeting claudin-18 isoform 2 (CLDN18.2). HRS-4642 binds non-covalently to KRAS G12D with high affinity, inhibiting its oncogenic signaling pathway, while SHR-A1904 delivers a DNA topoisomerase I inhibitor payload specifically to CLDN18.2-expressing tumor cells, facilitating cytotoxicity. The combination targets solid tumors, particularly those harboring KRAS G12D mutations, such as advanced pancreatic and gastric cancers. Clinical studies aim to evaluate synergy, safety, recommended dose, and anti-tumor efficacy in these populations[6][8][9][3].
- Other names
- HRS-4642 + SHR-A1904
02
Targets
KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)Claudin 18.2TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on HRS-4642 + SHR-A1904.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HRS-4642 + SHR-A1904.